Botulinum toxin type A
Botulinum neurotoxin type A (Botox, Dysport, Xeomin, Jeuveau, Daxxify)
Written by Aaron CuhaReviewed Sep 2026
Also known as: Botox, onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, prabotulinumtoxinA, daxibotulinumtoxinA
A 150 kDa bacterial enzyme, not a peptide, first approved in 1991 and carrying a boxed warning about toxin effects spreading beyond the injection site. Its therapeutic indications are far larger than its cosmetic ones: in the pooled PREEMPT chronic migraine trials, 1384 patients, headache days fell 8.4 versus 6.6 on placebo. Cosmetic efficacy is measured on subjective wrinkle scales at maximum frown and lasts roughly 3 to 6 months.
Overview
Botulinum toxin type A is included in this archive for one reason: topical peptides such as argireline are sold as alternatives to it, and that comparison needs an accurate reference point. So start with what it is. It is a 150 kDa protein produced by Clostridium botulinum, roughly eighty times the mass of a typical therapeutic peptide, and it is a zinc endopeptidase enzyme rather than a receptor ligand. It catalytically destroys its target inside the nerve terminal. A topically applied hexapeptide that must cross the stratum corneum and reach a motor nerve ending is not a weaker version of this. It is a different kind of thing, and the potency difference runs to many orders of magnitude.
Botox was approved under BLA 103000 on 9 December 1991, which is decades before the cosmetic use most people associate with it. Its therapeutic indication set is substantially larger than its cosmetic one and includes chronic migraine prophylaxis, overactive bladder and neurogenic detrusor overactivity, upper and lower limb spasticity in adults and children, cervical dystonia, severe primary axillary hyperhidrosis, blepharospasm and strabismus. The cosmetic approvals cover glabellar lines, lateral canthal lines, forehead lines and platysma bands.
All botulinum products carry an FDA boxed warning about distant spread of toxin effect: post-marketing reports describe effects consistent with botulism, including swallowing and breathing difficulties, occurring hours to weeks after injection, sometimes fatal, most often in children treated for spasticity. That warning applies to the cosmetic formulations too.
The cosmetic trial evidence is strong on its own terms and it is worth knowing what those terms are. Efficacy is rated on ordinal wrinkle-severity scales by an investigator and by the participant, at maximum frown. In READY-1, 297 adults, the month 1 composite response was 82.9 percent versus 0 percent on placebo. By month 6 that had fallen to 23.6 percent versus 1.5 percent, which is the honest picture of duration.
Mechanism of action
The heavy chain binds to receptors on cholinergic nerve terminals and the complex is internalised. The light chain, a zinc-dependent endopeptidase, then cleaves SNAP-25, one of the SNARE proteins required for acetylcholine-containing vesicles to fuse with the terminal membrane. Without intact SNAP-25 the vesicles cannot release their contents, so transmission fails and the target muscle or gland is functionally denervated. Because this is enzymatic, a very small number of molecules inactivates a large number of SNAP-25 targets, which is the source of the extreme potency. Recovery takes months and depends on the nerve terminal sprouting new endings and regenerating SNAP-25, not on the drug being cleared from the body.
Human evidence
One of the most thoroughly trialled injectables in medicine, across a therapeutic programme in migraine, bladder, spasticity and dystonia and a separate cosmetic programme in facial lines. The cosmetic endpoints are subjective ordinal scales at maximum expression, and the effect is temporary.
- PREEMPT pooled, 1384 adults with chronic migraine: headache days at week 24 fell 8.4 on toxin versus 6.6 on placebo, P below 0.001.
- READY-1, 297 adults, glabellar lines: month 1 composite response 82.9 percent versus 0 percent.
- READY-1 at month 6: investigator-rated none or mild in 23.6 percent versus 1.5 percent, so most of the effect is gone by then.
- Treatment-related adverse events in READY-1 were 3.6 percent and typically mild, in a healthy cosmetic population.
- A boxed warning for distant spread of toxin effect applies to every type A product, including cosmetic formulations.
What this does not tell you: Cosmetic efficacy is measured by investigator and subject wrinkle-severity ratings at maximum frown, which are subjective ordinal scales and not a measure of how a face looks at rest or how anyone else perceives it. Effect is temporary, roughly 3 to 6 months. Cosmetic trials enrol healthy adults and therefore say nothing about risk in neuromuscular disease, where the boxed warning is most relevant. Immunogenicity and secondary non-response develop in a minority with repeated dosing and are poorly quantified in the cosmetic literature. Units are not interchangeable between products, so dose comparisons across brands require care.
Reading the research record
The reason this page sits in a peptide archive is the argireline comparison, and it deserves to be made explicitly rather than implied.
Argireline is acetyl hexapeptide-8, six amino acids, applied topically, proposed to interfere with assembly of the SNARE complex. Botulinum toxin type A is a 150 kDa injected enzyme that catalytically cleaves SNAP-25 inside the nerve terminal, so a handful of molecules inactivates a very large number of targets. For a topical hexapeptide to do anything comparable it would have to cross the stratum corneum in quantity and reach a motor nerve ending. The two are not the same mechanism at different strengths; they are different categories of intervention, and the potency gap runs to many orders of magnitude.
The second point worth keeping straight is the size of the therapeutic programme. Most people meet this drug as a wrinkle treatment, and most coverage stops there. Its larger evidence base is in chronic migraine, overactive bladder, spasticity, cervical dystonia and hyperhidrosis, where the injections are larger, the doses higher and the boxed warning about distant spread most consequential. The cosmetic use is the small, visible corner of a much bigger drug.
The evidence, charted
Fig. 1 · evidence composition
3of 4 citations (75%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 3 distinct years, 2010 to 2024, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Key studies & citations
- Human2010
OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program
The therapeutic evidence that is usually left out of cosmetic coverage. Two multicentre phase 3 trials pooled, 1384 adults randomised 1 to 1 to onabotulinumtoxinA 155 to 195 units or placebo every 12 weeks. Mean change in headache days at week 24 was minus 8.4 versus minus 6.6 in favour of the toxin, P below 0.001, with significant differences at all other timepoints. Note that placebo also produced a large decrease, so the between-group difference is under two headache days per month.
Headache - Human2024
Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial in Glabellar Lines
297 adults randomised 3 to 1 to relabotulinumtoxinA 50 units or placebo, followed 6 months. Co-primary endpoints at month 1 at maximum frown: composite response of at least 2 grades improvement on both investigator and participant scales 82.9 percent versus 0 percent, and investigator-rated none or mild 96.3 percent versus 4.5 percent, both P below 0.001. At month 6, investigator-rated none or mild had fallen to 23.6 percent versus 1.5 percent. Treatment-related adverse events 3.6 percent, typically mild.
Aesthetic Surgery Journal - Review2023
Efficacy and Safety of Botulinum Toxin Type A for Treatment of Glabellar Lines: A Network Meta-Analysis of Randomized Controlled Trials
A network meta-analysis comparing type A products in glabellar lines. Useful as the cross-product comparison, and a reminder that units differ between brands and cannot be converted, so dose comparisons across products are not straightforward.
Aesthetic Plastic Surgery - Human2010
A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches
One of the two registered PREEMPT trials. Status COMPLETED, actual enrolment 679. Included to make the therapeutic programme traceable, since the pooled publication reports both trials together.
ClinicalTrials.gov
Frequently asked questions
Is botulinum toxin a peptide?
No. It is a 150 kDa bacterial protein and an enzyme, roughly eighty times the mass of a typical therapeutic peptide. It is covered here because topical peptides are marketed against it and the comparison needs an accurate reference point.
Can a topical peptide do what Botox does?
No. Botulinum toxin is injected and works catalytically, destroying SNAP-25 inside the nerve terminal, so a tiny quantity has a large and lasting effect. A topical hexapeptide has to cross the stratum corneum and reach a motor nerve ending to do anything at all, and the potency difference is many orders of magnitude. They are different categories of intervention, not the same one at different strengths.
Does it carry a boxed warning?
Yes. Every type A product carries an FDA boxed warning about distant spread of toxin effect, describing post-marketing reports of botulism-like symptoms including swallowing and breathing difficulties, hours to weeks after injection, occasionally fatal and most often in children treated for spasticity. The warning applies to cosmetic formulations too.
How long does it last?
Roughly 3 to 6 months, and the decline is visible in trial data. In READY-1 the investigator-rated none-or-mild response was 96.3 percent at month 1 and 23.6 percent at month 6. Recovery depends on nerve terminals regenerating, not on the drug clearing from the body.
What is it actually approved for besides wrinkles?
Chronic migraine prophylaxis, overactive bladder and neurogenic detrusor overactivity, upper and lower limb spasticity in adults and children, cervical dystonia, severe primary axillary hyperhidrosis, blepharospasm and strabismus. The therapeutic indication set is considerably larger than the cosmetic one, and it came first: the original approval dates to 1991.
Are Botox, Dysport and Xeomin interchangeable?
Not by dose. Units are defined by each manufacturer's own assay and do not convert between products, which is why a network meta-analysis of glabellar line trials is the only sensible way to compare them and why unit-for-unit substitution is unsafe.